|
1. Biologie
|
|
|
|
3.1 Prévention - Tabac
|
|
|
|
4. Dépistage, diagnostic et pronostic
|
|
|
Chromosomal Instability in Cancer [ESMO]
|
|
|
|
|
|
Development
of robust biomarkers enabling the full extent of chromosomal
instability dynamics is crucial to leverage its potential for patient
stratification and for exploiting this feature for direct therapeutic
intervention.
|
|
|
|
|
|
|
4.1 Dép., diag. & prono. - Prostate
|
|
|
|
5. Traitements
|
|
|
|
Objections to (Some) Drug Discovery AI [In the Pipeline]
|
|
|
|
|
|
I
doubt very strongly that I’m going to turn into a neural-network
programmer, but I don’t want to just ignore all that stuff, either,
because it could change very drastically by the next time I get around
to paying attention!
|
|
|
|
|
|
|
5.12.2 Immunothérapies - CAR-T
|
|
|
|
5.12.3 Immunothérapies-combinaisons
|
|
|
|
|
5.2 Pharma
|
|
|
Novartis appoints Elizabeth Barrett as Oncology Head [Novartis]
|
|
|
|
|
|
Mrs.
Barrett has held numerous leadership positions in the pharmaceutical
industry as well as in the consumer sector. In her most recent role at
Pfizer, she led the oncology business through a significant period of
growth achieved in less than three years.
|
|
|
|
|
|
|
|
5.3 Traitements - FDA, EMA, NICE...
|
|
|
CDER Report on Novel Approvals Highlights Firsts in 2017 [RAPS]
|
|
|
|
|
|
But
for the FDA critics who complain that the agency is too slow or falling
behind its foreign regulatory peers, CDER points to the fact that 100%
of new drugs were approved within the timelines set by the user fee
agreements, 61% were designated in one or more expedited categories of
Fast Track, Breakthrough, Priority Review and/or Accelerated Approval,
and 78% (36 of 46) were approved in the US before any other country.
|
|
|
|
|
|
|
|
5.9.5 IASLC
|
|
|
|
6. Lutte contre les cancers
|
|
|
|
6.1 Observation
|
|
|
|
Cancer Deaths Continue to Decline [Science-Based Medicine]
|
|
|
|
|
|
This
data does not fit the fearmongering narrative that we often confront on
SBM, that the toxic bogeyman de jour is making us sick. There is no
increase due to GMOs, vaccines, pesticides, or toxins in food. Cancer
rates are driven by smoking and other tobacco use, hepatitis C, UV
light, and other known risk factors.
|
|
|
|
|
|
|
6.6 Publications
|
|
|
Why Elsevier is a Library’s Best Friend [The Scholarly Kitchen]
|
|
|
|
|
|
This
is the basic trade-off: libraries have won administrative efficiencies
in exchange for the negotiating leverage of the largest publishers. It
sounds crazy, but it’s a win-win situation. The losers? Small
publishers, who cannot operate at the scale of Elsevier and its peers
and that have trouble getting libraries’ attention.
|
|
|
|
|
|
|
Funders should mandate open citations [Nature]
|
|
|
|
|
|
The
two most authoritative sources of citation data are Clarivate
Analytics’ Web of Science, which grew from the Science Citation Index
created by Eugene Garfield in 1964, and Elsevier’s Scopus, launched in
2004. Neither is open or comprehensive.
|
|
|
|
|
|
|
A Big Brother future for science publishing? [BMJ]
|
|
|
|
|
|
But
how, I wondered, can Elsevier continue to make such big profits from
science publishing? Now, I think I see. The company thinks that there
will be one company supplying publishing services to scientists—just as
there is one Amazon, one Google, and one Facebook; and Elsevier aims to
be that company.
|
|
|
|
|
|
|
6.7 DMP, Big Data & applis
|
|
|